Consider prescribing DUPIXENT for your patients with inadequately controlled severe asthma

DUPIXENT is indicated in patients 6  years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by raised blood eosinophils (EOS) and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high-dose (ages 6 to 11) inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment1

DUPIXENT is a fully human monoclonal antibody that binds specifically to the IL-4Rα subunit and inhibits IL-4 and IL-13 signalling1

The impact of severe asthma can differ from person to person2

  • Illustrative patient profiles. Not actual patients

    JULIE

    Clinical profile

    35 years old

    Severe asthma

    ≥5 annual exacerbations

    Current treatment: daily high-dose inhaled corticosteroid (ICS) plus long-acting ß2-agonist (LABA)

    Blood EOS level

    Total IgE

    Baseline FeNO

    Lung function (FEV1)

    150 cells/µL

    35 IU/mL

    35 ppb

    60%

     

  • Illustrative patient profiles. Not actual patients

    JULIE

    Impact

      I am fed up with taking so many medicines with no improvement  

    Frequent absences from work stopping her from progressing her career

    Fed up with the amount of medications she has taken for her severe asthma with little or no effect

    Finds it difficult to care for her three young children and always needs support from partner and other family members with childcare

    Tired and angry with lack of sleep as woken up numerous times at night

Patients like Julie can benefit from treatment with DUPIXENT

DUPIXENT significantly reduces asthma exacerbations, improves lung function and improves quality of life, compared to placebo3–6

DUPIXENT has a long-term safety profile observed in clinical studies of adults, adolescents and children1

EXPLORE DUPIXENT'S EFFICACY
EXPLORE DUPIXENT’S SAFETY PROFILE

INTRODUCING THE DUPIXENT PRE-FILLED PEN

DUPIXENT can be administered via
a pre-filled pen or a syringe1

Mode of action DUPIXENT

Have questions about how DUPIXENT works?

 

Find out more

Mode of action DUPIXENT

Have questions about how DUPIXENT works?
 


Find out more

Complexity of Type 2 inflammation

Learn more about the biomarkers involved in Type 2 inflammation.


Find out more

    A&E, accident and emergency; EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; IgE, Immunoglobulin E; IL, interleukin; IU, international units; LABA, long-acting ß2-agonist; ppb, parts per billion; R, receptor.

    References

    1. DUPIXENT Summary of Product Characteristics, Date last accessed: May 2023
    2. Asthma UK. What is severe asthma? Available at: https://www.asthma.org.uk/advice/severe-asthma/what-is-severe-asthma/#whatissevereasthma. Date last accessed: May 2023.
    3. Bourdin A, et al. Allergy. 2021;76(1):269–280.
    4. Sanofi Data on file. REF-98937. 2020.
    5. Rabe KF, et al. N Engl J Med. 2018;378(26):2475–2485.
    6. Bourdin A, et al. Allergy. 2021;76(1):269–280. Supplementary Appendix S1.

MAT-XU-2204825 (v1.0) | Date of preparation: May 2023